Last reviewed · How we verify

Cisplatin-Navelbine-Radiotherapy — Competitive Intelligence Brief

Cisplatin-Navelbine-Radiotherapy (Cisplatin-Navelbine-Radiotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy, Vinca alkaloid. Area: Oncology.

phase 2 Platinum-based chemotherapy, Vinca alkaloid DNA, Tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cisplatin-Navelbine-Radiotherapy (Cisplatin-Navelbine-Radiotherapy) — Hospices Civils de Lyon. Cisplatin works by crosslinking DNA, causing cell death, while Navelbine inhibits microtubule formation, disrupting cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cisplatin-Navelbine-Radiotherapy TARGET Cisplatin-Navelbine-Radiotherapy Hospices Civils de Lyon phase 2 Platinum-based chemotherapy, Vinca alkaloid DNA, Tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy, Vinca alkaloid class)

  1. Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cisplatin-Navelbine-Radiotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-navelbine-radiotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: